{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:33:49Z","timestamp":1790746429814,"version":"4.1.0"},"reference-count":46,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>\n                    <jats:italic>Context.\u2014<\/jats:italic>\n                    Megakaryocytes are the \u201challmark\u201d of Philadelphia chromosome\u2013negative myeloproliferative neoplasms, such as essential thrombocythemia, polycythemia vera, and primary myelofibrosis; their morphology in correlation with Janus kinase 2 (\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F) mutation as well as clinical and laboratory parameters remains unknown.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Objective.\u2014<\/jats:italic>\n                    To assess the morphology of megakaryocytes in bone marrow biopsies of patients with and without\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F mutation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Design.\u2014<\/jats:italic>\n                    Assessment of morphologic features of megakaryocytes in 112 bone marrow biopsies (52 essential thrombocythemia, 38 polycythemia vera, and 22 primary myelofibrosis) and correlation with clinical and laboratory data.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results.\u2014<\/jats:italic>\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F mutation was detected in 24 of 52 essential thrombocythemia cases (46.2%), 36 of 38 polycythemia vera cases (97.5%), and 14 of 22 primary myelofibrosis cases (63.6%). By investigating morphometric and clinical parameters using multivariate analysis, we found that higher hemoglobin concentration, higher white blood cell counts, and lower platelet counts were significantly associated with\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F. Striking morphologic similarities were found between polycythemia vera\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F and primary myelofibrosis\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F concerning the localization and cytoplasmic size of megakaryocytes. Although polycythemia vera\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F and essential thrombocythemia\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F shared similarities in localization, distribution, and amount of megakaryocytes, morphology was different. Megakaryocytic morphology also differed between primary myelofibrosis\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F and essential thrombocythemia\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion.\u2014<\/jats:italic>\n                    Our results indicate that primary myelofibrosis\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F and polycythemia vera\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F share pathogenetic pathways, resulting in morphologically similar megakaryocytes.\n                  <\/jats:p>","DOI":"10.5858\/arpa.2013-0018-oa","type":"journal-article","created":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T17:55:36Z","timestamp":1409334936000},"page":"1203-1209","source":"Crossref","is-referenced-by-count":23,"title":["Megakaryocytic Morphology and Clinical Parameters in Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis With and Without JAK2 V617F"],"prefix":"10.5858","volume":"138","author":[{"given":"Nataliya","family":"Vytrva","sequence":"first","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Stacher","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Regitnig","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Zinke-Cerwenka","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hojas","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hubmann","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Porwit","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Bjorkholm","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Hoefler","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Beham-Schmid","sequence":"additional","affiliation":[{"name":"From the Institute of Pathology (Drs Vytrva, Stacher, Regitnig, Hoefler, and Beham-Schmid) and the Division of Hematology, Department of Medicine (Dr Zinke-Cerwenka), Medical University of Graz, Graz, Austria; the Division of Hematology, Department of Medicine, General Hospital F\u00fcrstenfeld, F\u00fcrstenfeld, Austria (Dr Hojas); the Division of Hematology, Department of Medicine, General Hospital Leoben, Leoben, Austria (Dr Hubmann); and the Department of Pathology, Radiumhemmet (Dr Porwit)..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"1","key":"i1543-2165-138-9-1203-b01","series-title":"Leukemia","first-page":"14","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi\n              A,","year":"2008","unstructured":"Tefferi\n              A, \n            \n              Vardiman\n              JW. \n          \n          Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14\u201322."},{"key":"i1543-2165-138-9-1203-b02","series-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues","author":"Swerdlow\n              SH,","year":"2008","unstructured":"Swerdlow\n              SH, \n            \n              Campo\n              E, \n            \n              Harris\n              NL, \n            et al\n          . WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer;2008."},{"issue":"7037","key":"i1543-2165-138-9-1203-b03","series-title":"Nature","first-page":"1144","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James\n              C,","year":"2005","unstructured":"James\n              C, \n            \n              Ugo\n              V, \n            \n              Le Couedic\n              JP, \n            et al\n          . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144\u20131148."},{"issue":"9464","key":"i1543-2165-138-9-1203-b04","series-title":"Lancet","first-page":"1054","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter\n              EJ,","year":"2005","unstructured":"Baxter\n              EJ, \n            \n              Scott\n              LM, \n            \n              Campbell\n              PJ, \n            et al\n          . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054\u20131061."},{"issue":"4","key":"i1543-2165-138-9-1203-b05","series-title":"Cancer Cell","first-page":"387","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine\n              RL,","year":"2005","unstructured":"Levine\n              RL, \n            \n              Wadleigh\n              M, \n            \n              Cools\n              J, \n            et al\n          . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u2013397."},{"issue":"17","key":"i1543-2165-138-9-1203-b06","series-title":"N Engl J Med","first-page":"1779","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics\n              R,","year":"2005","unstructured":"Kralovics\n              R, \n            \n              Passamonti\n              F, \n            \n              Buser\n              AS, \n            et al\n          . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u20131790."},{"issue":"24","key":"i1543-2165-138-9-1203-b07","series-title":"J Biol Chem","first-page":"22788","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao\n              R,","year":"2005","unstructured":"Zhao\n              R, \n            \n              Xing\n              S, \n            \n              Li\n              Z, \n            et al\n          . Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788\u201322792."},{"issue":"49","key":"i1543-2165-138-9-1203-b08","series-title":"Oncogene","first-page":"5662","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane\n              SG,","year":"2000","unstructured":"Rane\n              SG, \n            \n              Reddy\n              EP. \n          \n          Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19(49):5662\u20135679."},{"issue":"12","key":"i1543-2165-138-9-1203-b09","series-title":"Genome Biol","first-page":"253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka\n              K,","year":"2004","unstructured":"Yamaoka\n              K, \n            \n              Saharinen\n              P, \n            \n              Pesu\n              M, \n            \n              Holt\n              VE\n              III, \n            \n              Silvennoinen\n              O, \n            \n              O'Shea\n              JJ. \n          \n          The Janus kinases (Jaks). Genome Biol. 2004;5(12):253."},{"issue":"10","key":"i1543-2165-138-9-1203-b10","series-title":"Leukemia","first-page":"1813","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science","volume":"22","author":"Kilpivaara\n              O,","year":"2008","unstructured":"Kilpivaara\n              O, \n            \n              Levine\n              RL. \n          \n          JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008;22(10):1813\u20131817."},{"issue":"2","key":"i1543-2165-138-9-1203-b11","series-title":"Pathobiology","first-page":"72","article-title":"Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers","volume":"74","author":"Hussein\n              K,","year":"2007","unstructured":"Hussein\n              K, \n            \n              Bock\n              O, \n            \n              Kreipe\n              H. \n          \n          Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Pathobiology. 2007;74(2):72\u201380."},{"issue":"5","key":"i1543-2165-138-9-1203-b12","series-title":"Cell Cycle","first-page":"550","article-title":"Oncogenes in myeloproliferative disorders","volume":"6","author":"Tefferi\n              A,","year":"2007","unstructured":"Tefferi\n              A, \n            \n              Gilliland\n              DG. \n          \n          Oncogenes in myeloproliferative disorders. Cell Cycle. 2007;6(5):550\u2013566."},{"issue":"6","key":"i1543-2165-138-9-1203-b13","series-title":"Blood","first-page":"1131","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos\n              FP,","year":"2010","unstructured":"Santos\n              FP, \n            \n              Kantarjian\n              HM, \n            \n              Jain\n              N, \n            et al\n          . Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. Blood. 2010;115(6):1131\u20131136."},{"issue":"1","key":"i1543-2165-138-9-1203-b14","series-title":"Blood","first-page":"381","article-title":"Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis","volume":"99","author":"Beham-Schmid\n              C,","year":"2002","unstructured":"Beham-Schmid\n              C, \n            \n              Apfelbeck\n              U, \n            \n              Sill\n              H, \n            et al\n          . Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002;99(1):381\u2013383."},{"key":"i1543-2165-138-9-1203-b15","series-title":"Die Knochenmarksbiopsie","author":"Bartl\n              R,","year":"1984","unstructured":"Bartl\n              R, \n            \n              Frisch\n              B, \n            \n              Burkardt\n              R. \n          \n          Die Knochenmarksbiopsie. Basel, Switzerland: Karger;1984."},{"issue":"3","key":"i1543-2165-138-9-1203-b16","series-title":"J Clin Pathol","first-page":"269","article-title":"Are routine iron stains on bone marrow trephine biopsy specimens necessary?","volume":"58","author":"Stuart-Smith\n              SE,","year":"2005","unstructured":"Stuart-Smith\n              SE, \n            \n              Hughes\n              DA, \n            \n              Bain\n              BJ. \n          \n          Are routine iron stains on bone marrow trephine biopsy specimens necessary?\n          J Clin Pathol. 2005;58(3):269\u2013272."},{"key":"i1543-2165-138-9-1203-b17","series-title":"ImageJ","author":"Rasband\n              W.","year":"2008","unstructured":"Rasband\n              W. \n          \n          ImageJ\n           [computer program]. Bethesda, MD: National Institutes of Health; 2008. http:\/\/rsbweb.nih.gov\/ij\/. Accessed January 7, 2013."},{"issue":"3","key":"i1543-2165-138-9-1203-b18","series-title":"Anal Quant Cytol","first-page":"155","article-title":"Megakaryopoiesis in chronic myeloproliferative diseases: a morphometric evaluation with special emphasis on primary thrombocythemia","volume":"6","author":"Thiele\n              J,","year":"1984","unstructured":"Thiele\n              J, \n            \n              Funke\n              S, \n            \n              Holgado\n              S, \n            \n              Choritz\n              H, \n            \n              Georgii\n              A. \n          \n          Megakaryopoiesis in chronic myeloproliferative diseases: a morphometric evaluation with special emphasis on primary thrombocythemia. Anal Quant Cytol. 1984;6(3):155\u2013167."},{"issue":"5","key":"i1543-2165-138-9-1203-b19","series-title":"Virchows Arch A Pathol Anat Histopathol","first-page":"407","article-title":"Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis\u2013features of significance for the diagnosis of primary (essential) thrombocythaemia","volume":"413","author":"Thiele\n              J,","year":"1988","unstructured":"Thiele\n              J, \n            \n              Schneider\n              G, \n            \n              Hoeppner\n              B, \n            \n              Wienhold\n              S, \n            \n              Zankovich\n              R, \n            \n              Fischer\n              R. \n          \n          Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis\u2013features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch A Pathol Anat Histopathol. 1988;413(5):407\u2013417."},{"issue":"3","key":"i1543-2165-138-9-1203-b20","series-title":"Am J Clin Pathol","first-page":"336","article-title":"The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia","volume":"130","author":"Gianelli\n              U,","year":"2008","unstructured":"Gianelli\n              U, \n            \n              Iurlo\n              A, \n            \n              Vener\n              C, \n            et al\n          . The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130(3):336\u2013342."},{"issue":"2","key":"i1543-2165-138-9-1203-b21","series-title":"Int J Hematol","first-page":"130","article-title":"The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more \u201cerythremic\u201d and less \u201cthrombocythemic\u201d: a molecular, histologic, and clinical study","volume":"86","author":"Rudzki\n              Z,","year":"2007","unstructured":"Rudzki\n              Z, \n            \n              Sacha\n              T, \n            \n              Stoj\n              A, \n            et al\n          . The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more \u201cerythremic\u201d and less \u201cthrombocythemic\u201d: a molecular, histologic, and clinical study. Int J Hematol. 2007;86(2):130\u2013136."},{"issue":"4","key":"i1543-2165-138-9-1203-b22","series-title":"Acta Hematol","first-page":"218","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms","volume":"119","author":"Koppikar\n              P,","year":"2008","unstructured":"Koppikar\n              P, \n            \n              Levine\n              RL. \n          \n          JAK2 and MPL mutations in myeloproliferative neoplasms. Acta Hematol. 2008;119(4):218\u2013225."},{"key":"i1543-2165-138-9-1203-b23","series-title":"Immunol Rev","first-page":"132","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu\n              M,","year":"2008","unstructured":"Pesu\n              M, \n            \n              Laurence\n              A, \n            \n              Kishore\n              N, \n            \n              Zwillich\n              SH, \n            \n              Chan\n              G, \n            \n              O'Shea\n              JJ. \n          \n          Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132\u2013142."},{"issue":"1","key":"i1543-2165-138-9-1203-b01","series-title":"Leukemia","first-page":"14","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi\n              A,","year":"2008","unstructured":"Tefferi\n              A, \n            \n              Vardiman\n              JW. \n          \n          Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14\u201322."},{"key":"i1543-2165-138-9-1203-b02","series-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues","author":"Swerdlow\n              SH,","year":"2008","unstructured":"Swerdlow\n              SH, \n            \n              Campo\n              E, \n            \n              Harris\n              NL, \n            et al\n          . WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer;2008."},{"issue":"7037","key":"i1543-2165-138-9-1203-b03","series-title":"Nature","first-page":"1144","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James\n              C,","year":"2005","unstructured":"James\n              C, \n            \n              Ugo\n              V, \n            \n              Le Couedic\n              JP, \n            et al\n          . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144\u20131148."},{"issue":"9464","key":"i1543-2165-138-9-1203-b04","series-title":"Lancet","first-page":"1054","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter\n              EJ,","year":"2005","unstructured":"Baxter\n              EJ, \n            \n              Scott\n              LM, \n            \n              Campbell\n              PJ, \n            et al\n          . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054\u20131061."},{"issue":"4","key":"i1543-2165-138-9-1203-b05","series-title":"Cancer Cell","first-page":"387","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine\n              RL,","year":"2005","unstructured":"Levine\n              RL, \n            \n              Wadleigh\n              M, \n            \n              Cools\n              J, \n            et al\n          . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u2013397."},{"issue":"17","key":"i1543-2165-138-9-1203-b06","series-title":"N Engl J Med","first-page":"1779","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics\n              R,","year":"2005","unstructured":"Kralovics\n              R, \n            \n              Passamonti\n              F, \n            \n              Buser\n              AS, \n            et al\n          . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u20131790."},{"issue":"24","key":"i1543-2165-138-9-1203-b07","series-title":"J Biol Chem","first-page":"22788","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao\n              R,","year":"2005","unstructured":"Zhao\n              R, \n            \n              Xing\n              S, \n            \n              Li\n              Z, \n            et al\n          . Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788\u201322792."},{"issue":"49","key":"i1543-2165-138-9-1203-b08","series-title":"Oncogene","first-page":"5662","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane\n              SG,","year":"2000","unstructured":"Rane\n              SG, \n            \n              Reddy\n              EP. \n          \n          Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19(49):5662\u20135679."},{"issue":"12","key":"i1543-2165-138-9-1203-b09","series-title":"Genome Biol","first-page":"253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka\n              K,","year":"2004","unstructured":"Yamaoka\n              K, \n            \n              Saharinen\n              P, \n            \n              Pesu\n              M, \n            \n              Holt\n              VE\n              III, \n            \n              Silvennoinen\n              O, \n            \n              O'Shea\n              JJ. \n          \n          The Janus kinases (Jaks). Genome Biol. 2004;5(12):253."},{"issue":"10","key":"i1543-2165-138-9-1203-b10","series-title":"Leukemia","first-page":"1813","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science","volume":"22","author":"Kilpivaara\n              O,","year":"2008","unstructured":"Kilpivaara\n              O, \n            \n              Levine\n              RL. \n          \n          JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008;22(10):1813\u20131817."},{"issue":"2","key":"i1543-2165-138-9-1203-b11","series-title":"Pathobiology","first-page":"72","article-title":"Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers","volume":"74","author":"Hussein\n              K,","year":"2007","unstructured":"Hussein\n              K, \n            \n              Bock\n              O, \n            \n              Kreipe\n              H. \n          \n          Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Pathobiology. 2007;74(2):72\u201380."},{"issue":"5","key":"i1543-2165-138-9-1203-b12","series-title":"Cell Cycle","first-page":"550","article-title":"Oncogenes in myeloproliferative disorders","volume":"6","author":"Tefferi\n              A,","year":"2007","unstructured":"Tefferi\n              A, \n            \n              Gilliland\n              DG. \n          \n          Oncogenes in myeloproliferative disorders. Cell Cycle. 2007;6(5):550\u2013566."},{"issue":"6","key":"i1543-2165-138-9-1203-b13","series-title":"Blood","first-page":"1131","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos\n              FP,","year":"2010","unstructured":"Santos\n              FP, \n            \n              Kantarjian\n              HM, \n            \n              Jain\n              N, \n            et al\n          . Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. Blood. 2010;115(6):1131\u20131136."},{"issue":"1","key":"i1543-2165-138-9-1203-b14","series-title":"Blood","first-page":"381","article-title":"Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis","volume":"99","author":"Beham-Schmid\n              C,","year":"2002","unstructured":"Beham-Schmid\n              C, \n            \n              Apfelbeck\n              U, \n            \n              Sill\n              H, \n            et al\n          . Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002;99(1):381\u2013383."},{"key":"i1543-2165-138-9-1203-b15","series-title":"Die Knochenmarksbiopsie","author":"Bartl\n              R,","year":"1984","unstructured":"Bartl\n              R, \n            \n              Frisch\n              B, \n            \n              Burkardt\n              R. \n          \n          Die Knochenmarksbiopsie. Basel, Switzerland: Karger;1984."},{"issue":"3","key":"i1543-2165-138-9-1203-b16","series-title":"J Clin Pathol","first-page":"269","article-title":"Are routine iron stains on bone marrow trephine biopsy specimens necessary?","volume":"58","author":"Stuart-Smith\n              SE,","year":"2005","unstructured":"Stuart-Smith\n              SE, \n            \n              Hughes\n              DA, \n            \n              Bain\n              BJ. \n          \n          Are routine iron stains on bone marrow trephine biopsy specimens necessary?\n          J Clin Pathol. 2005;58(3):269\u2013272."},{"key":"i1543-2165-138-9-1203-b17","series-title":"ImageJ","author":"Rasband\n              W.","year":"2008","unstructured":"Rasband\n              W. \n          \n          ImageJ\n           [computer program]. Bethesda, MD: National Institutes of Health; 2008. http:\/\/rsbweb.nih.gov\/ij\/. Accessed January 7, 2013."},{"issue":"3","key":"i1543-2165-138-9-1203-b18","series-title":"Anal Quant Cytol","first-page":"155","article-title":"Megakaryopoiesis in chronic myeloproliferative diseases: a morphometric evaluation with special emphasis on primary thrombocythemia","volume":"6","author":"Thiele\n              J,","year":"1984","unstructured":"Thiele\n              J, \n            \n              Funke\n              S, \n            \n              Holgado\n              S, \n            \n              Choritz\n              H, \n            \n              Georgii\n              A. \n          \n          Megakaryopoiesis in chronic myeloproliferative diseases: a morphometric evaluation with special emphasis on primary thrombocythemia. Anal Quant Cytol. 1984;6(3):155\u2013167."},{"issue":"5","key":"i1543-2165-138-9-1203-b19","series-title":"Virchows Arch A Pathol Anat Histopathol","first-page":"407","article-title":"Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis\u2013features of significance for the diagnosis of primary (essential) thrombocythaemia","volume":"413","author":"Thiele\n              J,","year":"1988","unstructured":"Thiele\n              J, \n            \n              Schneider\n              G, \n            \n              Hoeppner\n              B, \n            \n              Wienhold\n              S, \n            \n              Zankovich\n              R, \n            \n              Fischer\n              R. \n          \n          Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis\u2013features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch A Pathol Anat Histopathol. 1988;413(5):407\u2013417."},{"issue":"3","key":"i1543-2165-138-9-1203-b20","series-title":"Am J Clin Pathol","first-page":"336","article-title":"The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia","volume":"130","author":"Gianelli\n              U,","year":"2008","unstructured":"Gianelli\n              U, \n            \n              Iurlo\n              A, \n            \n              Vener\n              C, \n            et al\n          . The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130(3):336\u2013342."},{"issue":"2","key":"i1543-2165-138-9-1203-b21","series-title":"Int J Hematol","first-page":"130","article-title":"The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more \u201cerythremic\u201d and less \u201cthrombocythemic\u201d: a molecular, histologic, and clinical study","volume":"86","author":"Rudzki\n              Z,","year":"2007","unstructured":"Rudzki\n              Z, \n            \n              Sacha\n              T, \n            \n              Stoj\n              A, \n            et al\n          . The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more \u201cerythremic\u201d and less \u201cthrombocythemic\u201d: a molecular, histologic, and clinical study. Int J Hematol. 2007;86(2):130\u2013136."},{"issue":"4","key":"i1543-2165-138-9-1203-b22","series-title":"Acta Hematol","first-page":"218","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms","volume":"119","author":"Koppikar\n              P,","year":"2008","unstructured":"Koppikar\n              P, \n            \n              Levine\n              RL. \n          \n          JAK2 and MPL mutations in myeloproliferative neoplasms. Acta Hematol. 2008;119(4):218\u2013225."},{"key":"i1543-2165-138-9-1203-b23","series-title":"Immunol Rev","first-page":"132","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu\n              M,","year":"2008","unstructured":"Pesu\n              M, \n            \n              Laurence\n              A, \n            \n              Kishore\n              N, \n            \n              Zwillich\n              SH, \n            \n              Chan\n              G, \n            \n              O'Shea\n              JJ. \n          \n          Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132\u2013142."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/138\/9\/article-p1203.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/138\/9\/article-p1203.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/138\/9\/article-p1203.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:02:37Z","timestamp":1770771757000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/138\/9\/article-p1203.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":46,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2013-0018-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}